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Objectives:We examined the associations between treatment attitudes and beliefs with race–gender dif-
ferences in antidepressant adherence.
Methods: Subjects (n= 186) were African-American and White subjects aged ≥60 years, diagnosed with
clinically signiﬁcant depression, and had a new outpatient primary care recommendation for antide-
pressant treatment. Antidepressant adherence was assessed using the Brief Medication Questionnaire.
Attitudes and beliefs were assessed using the Patients Attitudes Toward and Ratings of Care for Depres-
sion, two items rating perceived medication importance, and a modiﬁed version of the Stigma Scale for
Receiving Psychological Help.
Results: African-American men and women had signiﬁcantly greater concerns about antidepressants
and signiﬁcantly less understanding about treatment than White women. African-American men had
signiﬁcantly more negative attitudes toward healthcare providers than African-American and White
women. African-American women were more likely than White men and women to endorse a medica-
tion other than their antidepressant as most important. Whereas some race–gender differences were
found in personal spirituality, no group differences were found in perceived stigma. In a logistic regres-
sion model adjusted for key baseline variables, White women were signiﬁcantly more adherent to anti-
depressants than African-American women (OR= 3.05, 95% CI= 1.06–8.81). Fewer concerns about
antidepressants and indicating the antidepressant as the most important medication were both signiﬁ-
cantly associated with adherence. After including either of these two variables, the adherence difference
between White women and African-American women was no longer signiﬁcant (OR= 2.56, 95%
CI = 0.84–7.80).
Conclusions: Concerns about antidepressants and the importance of antidepressant medication are as-
sociated with adherence and are potentially modiﬁable through improved patient–provider communi-
cation, psycho-education, and therapeutic interventions. Copyright # 2013 John Wiley & Sons, Ltd.
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Introduction
Depression is common in older adults (Meeks et al.,
2011, Thielke et al., 2010) and related to increased
functional impairment, poorer quality of life, mortality
due to physical illness, and suicide (Schulz et al., 2000,
Rovner et al., 1991, Penninx et al., 2001, Cronin-
Stubbs et al., 2000, Gallo et al., 2008). Primary care
physicians (PCPs) provide the majority of later-life de-
pression treatment, particularly for African Americans
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(Luber et al., 2001, Areán et al., 2002, Neighbors et al.,
2008). Antidepressants are often the evidence-based
choice for older adults seen in primary care settings
(Alvidrez and Areán, 2002); however, non-adherence
is common, with estimates ranging from 40% to 75%
(Pampallona et al., 2002). Racial differences in the
use of antidepressant medications may exist, in that
African-American patients ﬁnd antidepressant treat-
ment less acceptable (Cooper et al., 2003) and they
are less likely to be taking antidepressants (Blazer
et al., 2000) than White elders.
Models of health behaviors, such as the Theory of
Reasoned Action (Ajzen, 1996), posit that behavioral
intention (critical for treatment adherence) is deter-
mined by a person’s weighing of potential risks and
beneﬁts of the behavior (Cooper et al., 2003, Van
Voorhees et al., 2009). Zivin and Kales’ adaptation
(2008) of the Theory of Reasoned Action divides fac-
tors impacting health behaviors according to their
potential modiﬁability by intervention as follows:
(i) modiﬁable (beliefs and attitudes); (ii) potentially
modiﬁable (e.g. psychiatric and medical comorbidity);
and (iii) non-modiﬁable (gender and race). In our prior
study (Kales et al., 2012), we examined the role of po-
tentially modiﬁable and non-modiﬁable factors on anti-
depressant adherence and found that after controlling
for demographic, illness, and functional status variables,
there were signiﬁcant differences in adherence between
African-American andWhite older women. In the pres-
ent study, we sought to examine the associations be-
tween the race–gender differences in adherence we
previously found and attitudes and beliefs.
Older African Americans with depression report less
favorable attitudes toward seeking treatment than older
Whites, are more likely to express mistrust in mental
health services, and believe that mental health treatment
is not the most effective symptom reduction strategy
(Conner et al., 2010). Past work among African-
American primary care patients found that concerns
with antidepressant medication, such as side effects
and potential for addiction, were extremely important
considerations for depression care (Cooper et al., 2000)
and that African Americans were less likely to view de-
pression medication as beneﬁcial (Kasckow et al., 2011).
Older adults may also prioritize physical health over
mental health treatment. In a study of community-
dwelling older adults who were asked to assess their
life problems, 41% ranked physical health as their
most important problem, whereas only 6% ranked
depression as most important (Proctor et al., 2008);
this study did not examine racial differences in the
ranking of life problems. In the present study, we
sought to examine if the treatment attitude that taking
antidepressants was less important thanmedications for
physical conditions was associated with race–gender dif-
ferences in adherence.
Perceived stigma includes beliefs about the devalu-
ation of and discrimination toward individuals with
mental illness (Sirey et al., 2001b). There is an inverse
relationship between perceived stigma and mental
health treatment seeking (Brown et al., 2010, Conner
et al., 2010, Cooper et al., 2003). High levels of per-
ceived stigma have been signiﬁcantly related to nega-
tive treatment attitudes in older African Americans
(Conner et al., 2010). Sirey et al. found that high levels
of perceived stigma at the start of treatment predicted
early treatment discontinuation among older adults
with major depression (Sirey et al., 2001a). However,
there are limited data on how the relationship between
stigma and adherence is affected by race.
There is some evidence to suggest that spiritual be-
liefs may also play a role in racial differences in antide-
pressant adherence. In a study of African-American
older adults in primary care, Wittink et al. (2009) found
that religious beliefs inﬂuenced how subjects conceptu-
alized depression and how they engaged in treatment.
Older African Americans conceptualized depression as
a spiritual crisis characterized by a loss of faith.
Regaining faith and participating religious activities
such as prayer or attending church were identiﬁed as
ways depression could be relieved (Wittink et al.,
2009). African Americans have been found to rate per-
sonal or intrinsic spirituality among the most important
aspects of depression care (Cooper et al., 2000, Cooper
et al., 2001). There are limited data available on the re-
lationship between spirituality and adherence, including
the role of race–gender, in older adults.
In the present study of older adults with depression
who were diagnosed in primary care settings and
recommended antidepressant treatment, we examined
treatment attitudes (including treatment concerns and
prioritizing medications) and beliefs (including stigma
and spirituality) as potentially associated with the race–
gender differences in antidepressant adherence found
in our previous study (Kales et al., 2012). We hypothe-
sized that poorer attitudes about treatment, greater con-
cerns about stigma, and greater personal spirituality
would account for these race–gender differences.
Methods
Subjects
This study used the same sample as the Kales et al.
(2012) study. Subjects were recruited between March
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2007 and March 2010 from 13 primary care clinics
located in Ann Arbor, Michigan and surrounding
communities. Inclusion criteria were as follows:
(i) adults aged 60 years and over; (ii) a diagnosis of
clinically signiﬁcant depression; (iii) seen in a partic-
ipating primary care clinic; and (iv) a new recom-
mendation for antidepressant treatment by the PCP.
Clinically signiﬁcant depression was deﬁned as having
the following: (i) a new antidepressant prescription
from the PCP (encompassing newly diagnosed patients
as well as patients with recurrent depression receiv-
ing a new antidepressant prescription for a current
depressive episode) and (ii) a score of 5 or higher
on the Geriatric Depression Scale—Short Form
(Sheikh and Yesavage, 1986). Exclusion criteria
included the following: (i) patients with active
suicidal ideation, psychosis, a history of mania, or
cognitive impairment (>3 errors on the Six Item
Screener (Callahan et al., 2002)); (ii) race other than
White or African American; or (iii) the inability to
communicate in English.
Subjects were directly referred to the study by
their PCPs or identiﬁed through the electronic
medical record. Our methods for identifying poten-
tial subjects using electronic medical records have
been previously reported (Seyfried et al., 2009). Af-
ter obtaining PCP consent, subjects were contacted
by study staff and recruited via mail and telephone.
The methods of this study were approved by the
University of Michigan Medical School Institutional
Review Board.
Assessments
Subjects were assessed at baseline and 4-month follow-
up. The baseline interview assessed the following:
(i) demographic variables including age, race, gender,
marital status, and education; (ii) illness variables in-
cluding past antidepressant use, number of prescribed
medications, physical health status (SF-12 physical
component scale), mental health status (SF-12 mental
component scale) (Ware et al., 1996), comorbid
anxiety (anxiety items of the Hospital Anxiety and
Depression Scale (HADS-A) (Zigmond, 1983)), somatic
anxiety (Anxiety Sensitivity Index—Revised (ASI-R);
subscales pertaining to beliefs and fears about somatic
sensations) (Deacon et al., 2003), and further assess-
ment of depression using the Patient Health Question-
naire depression scale (Kroenke et al., 2001);
(iii) functional assessment including instrumental
(IADL) (Lawton and Brody, 1969) and basic (Katz
ADL) (Katz, 1970) activities of daily living and
executive function (Wechsler Letter-Number Se-
quencing subscale) (Wechsler, 1997); and (iv) atti-
tudes and beliefs toward depression treatment
including perceived stigma and personal spirituality.
Attitudes toward depression care were assessed using
a validated patient-centered instrument, the 30-item
Patients Attitude Toward and Ratings of Care for
Depression (PARC-D) (Cooper et al., 2000). Each
item on this instrument is scored on a 5-point
Likert scale, with higher scores indicating more
positive attitudes toward depression treatment and
the prescribing physician. The PARC-D includes
the following seven subscales: (i) Healthcare Pro-
viders’ Interpersonal Skills; (2) Treatment Effective-
ness; (3) Access; (4) Treatment Problems; (5) PCP
Recognition of Depression; (6) Patient Education,
Information, and Understanding; and (7) Intrinsic
Spirituality. To explore patient attitudes about the
importance of their depression medications, two
items were included to assess which currently pre-
scribed medications patients considered the two
most important and the two least important, yield-
ing three mutually exclusive groups: (i) those who
consider antidepressant most important; (ii) those
who consider antidepressant as least important;
and (iii) those who consider medications other than
antidepressants most important.
Perceived stigma was assessed using the Stigma
Scale for Receiving Psychological Help, modiﬁed for
depression treatment. Each item on this instrument
is scored on a 4-point Likert scale (total scores range
between 0 and 15) with higher scores indicating
greater perceived stigma (Pyne et al., 2004).
Adherence assessment
The dependent variable for this study was a dichoto-
mous indicator of antidepressant adherence (adherent/
non-adherent) at 4-month follow-up. Antidepressant
adherence was assessed at 4months, as the early treat-
ment phase is a particularly critical time period with
increased risk of treatment dropout, medication discon-
tinuation (Sirey et al., 2001a, Sirey et al., 2001b), and
vulnerability to suicide (Valenstein et al., 2009). Adher-
ence was measured using the validated self-report
adherence question from the Brief Medication Ques-
tionnaire (BMQ) (Svarstad et al., 1999) that asks how
consistently the subject took their medication on a daily
basis in the week prior to the interview. This item is sig-
niﬁcantly correlated with pharmacy reﬁll records
(Rickles and Svarstad, 2007). Consistent with prior
studies that consider an antidepressant medication
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possession ratio of ≥80% to be adequate, we rated those
as missing 0–1 daily dose in a given week as adherent
(Valenstein et al., 2002). Subjects who chose to never
initiate the antidepressant medication by not ﬁlling the
prescription or not ever taking the medication were
considered non-adherent.
Statistical analysis
In our prior study (Kales et al., 2012), after adjusting
for other covariates, we did not ﬁnd race, gender, or
an interaction of race by gender to be signiﬁcantly as-
sociated with adherence. However, upon examining
the antidepressant adherence difference across four
race–gender subgroups, we found that White women
were 3.1 times more likely than African-American
women to be adherent to their antidepressant medica-
tion (OR= 3.05, 95% CI= 1.06–8.81, p= 0.0389) even
after adjusting for demographic characteristics, base-
line illness, and function variables (but not for
attitude-related variables). None of the other race–
gender pairs were signiﬁcantly associated with
adherence. Because of the signiﬁcant differences in
antidepressant adherence between White and
African-American women in our previous study
(Kales et al., 2012), in the present study, we examined
the impact of attitudes and beliefs on adherence across
four distinct race–gender subgroups (African-Ameri-
can women, African-American men, White women,
and White men). Descriptive statistics were obtained
for baseline characteristics, including attitudes and be-
liefs, by race–gender subgroups. Differences in base-
line variables across the race–gender subgroups were
assessed using analysis of variance or chi-square tests.
We then performed logistic regression analysis with
adherence as the dependent variable and race–gender
subgroups as the primary predictors, adjusting for
the baseline demographic, illness, and functional as-
sessment variables. Next, we individually examined
the associations between adherence and (i) perceived
stigma, (ii) each of the seven subscales of PARC-D,
and (iii) the medication importance groups. Lastly,
we added the attitude and belief variables that were
signiﬁcant (p< 0.05) to the model with race–gender
subgroups. Because 15% of subjects were missing par-
tial data for at least one covariate such as anxiety, we
applied a multiple imputation strategy using the MI
procedure in SAS (SAS Institute Inc., Cary, NC) under
a multivariate normal model that included all covariates
as well as adherence. The logistic regression estimates
were pooled across ﬁve imputation samples using
Rubin’s method (Rubin, 1987).
Results
Sample characteristics
The study included 198 adults aged ≥60 years who were
seen in primary care clinics, with diagnoses of clinically
signiﬁcant depression and newly recommended antide-
pressant treatment by their PCPs. Of these, 10 were lost
to follow-up, and another 2 refused to answer the
question concerning medication importance, leaving
186 participants. The 12 patients not included in
these analyses did not differ signiﬁcantly from the other
186 patients in education, marital status, or past antide-
pressant use. However, they were younger (63.6 vs.
67.3 years old, p=0.0019), less anxious (ASI-R total
38.0 vs. 51.8, p=0.0496), less disabled (Katz ADL total
6.0 vs. 5.6, p< 0.0001; IADL 7.9 vs. 7.3, p< 0.0001),
and had higher perceived stigma (8.5 vs. 6.9, p=0.0475)
and lower intrinsic spirituality (4.5 vs. 5.9, p=0.0258).
Table 1 displays complete demographic, illness, and func-
tion variables for the study sample.
Determinants of antidepressant adherence
Table 2 reports summary statistics of treatment attitudes
and beliefs potentially associated with antidepressant
adherence across the four race–gender subgroups.
Noting only the signiﬁcant difference at an overall
a of 0.05 after adjusting for six multiple between
race–gender subgroup comparisons, African-American
women and men scored signiﬁcantly lower than White
women (corresponding to less positive attitudes)
on attitude subscales that assessed concerns about
antidepressants (Treatment Problems subscale) and
understanding about treatment (Patient Education,
Information, and Understanding). African-American
men scored signiﬁcantly lower than African-American
and White women on attitudes toward health providers
(Healthcare Providers’ Interpersonal Skills), and
African-American women were signiﬁcantly less likely
than White women and White men to indicate the
antidepressant medication was their most important
medication. African-American women had higher
levels of intrinsic spirituality than White women
and White men, and African-American men had
higher levels of intrinsic spirituality than White
women. No race–gender differences were found in
attitudes regarding treatment effectiveness, access, and
recognition of depression. No race–gender differences
were found in perceived stigma.
Table 3 displays ﬁndings from logistic regression
models predicting 4-month adherence using each of
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treatment attitude and belief variables. Of the PARC-D
subscales, those patients who endorsed fewer concerns
with antidepressants (treatment problems) were more
likely to be adherent (OR=1.27, 95% CI= 1.06–1.52,
p< 0.01). Additionally, those who indicated that their
antidepressant was the “most important” medication
were signiﬁcantly more likely to be adherent than
those who indicated that their antidepressant was
the “least important” medication (OR=4.96, 95%
CI= 1.59–15.47, p< 0.01). Perceived stigma was not
signiﬁcantly associated with antidepressant treatment
adherence after adjusting for baseline covariates.
Independent of baseline demographic, illness, and
functional status variables, the PARC-D Treatment
Problems subscale (indicating antidepressant con-
cerns) and the medication importance item were
highly correlated with each other. Those who identi-
ﬁed their antidepressant as the “most important”
medication had fewer concerns about antidepressant
treatment (p< .01). Because of the high correlation
Table 1 Subjects’ characteristics at baseline by race–gender groups
AA women
(N=44)
AA men
(N=37)
White women
(N=57)
White men
(N=48)
Age (years)
60–64 46% 68% 44% 48%
65–74 43% 22% 35% 25%
75–90 11% 11% 21% 27%
Education (high school or below) 45% 41% 30% 40%
Marital status* (with partner/spouse) 32% 49% 49% 65%
With prior depression treatment* 62% 51% 84% 69%
Seeing a therapist* 5% 35% 16% 12%
Number of prescribed medications 4.4 4.0 4.2 4.5
Short Form-36 Physical component summary (PCS) 36.0 36.5 37.7 38.3
Short Form-36 Mental component summary (MCS) 36.1 35.3 38.9 38.8
Depression score on Patient Health Questionnaire (PHQ) 13.1 13.0 11.4 11.2
Hospital Anxiety and Depression Scale (HADS) 8.7 9.9 9.5 8.6
Anxiety Sensitivity Index (ASI)* 60.3 58.8 47.1 44.4
Katz index of independence in activities of daily living 5.5 5.6 5.7 5.7
Instrumental activities of daily living scale (IADL) 6.8 7.3 7.5 7.2
Weschler memory scale* 6.8 7.8 10.4 8.6
Cell values are means unless otherwise speciﬁed.
AA, African Americans.
*p< 0.05 for four-group comparison.
Table 2 Stigma, attitudes, and drug identiﬁed as most/least important by race–gender subgroups
AA women
(N=44)
AA men
(N=37)
White women
(N=57)
White men
(N=48)
Perceived stigma 7.3 7.2 6.2 7.3
Attitude toward depression treatment and doctors
Intrinsic spiritualitya,c,d 6.9 6.6 5.0 5.6
Treatment problemsa,d 8.3 8.3 9.9 9.3
Treatment effectiveness 12.4 12.1 12.7 12.1
Health providers’ interpersonal skillsb,d 22.0 20.2 22.9 21.4
Patient education, information, and understandinga,d 5.7 5.6 6.7 5.9
Access 6.7 6.3 7.1 7.0
Recognition of depression 7.8 7.1 7.8 7.6
Drugs identified as most/least important (%)a,c
AD as most important 6.8 24.3 35.1 31.3
AD as least important 18.2 16.2 19.3 16.7
Other drugs as most important 75.0 59.5 45.6 52.1
No differences were found in any of treatment attitude or belief variables between genders in Whites or between races in men.
aIndicates signiﬁcant differences (p< 0.05 after adjusting for multiple comparison using Tukey’s method) between African-American women versus
White women.
bAfrican-American women versus African-American men.
cAfrican-American women versus White men.
dWhite women versus African-American men.
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between the two measures, we added them each in a
separate logistic regression model with race–gender
subgroups, adjusting for baseline demographic, illness,
and functional variables. In the ﬁrst model, the Treat-
ment Problems subscale remained signiﬁcantly associ-
ated with adherence (OR= 1.26, 95% CI= 1.04–1.51);
in the second model, indicating the antidepressant as
most important medication also remained signiﬁ-
cantly associated with adherence (OR= 4.48, 95%
CI= 1.40–14.30). Further, after inclusion of either of
the two variables, the adherence disparity between
White and African-American women was no longer
statistically signiﬁcant.
Discussion
Our previous study found race–gender differences in
antidepressant adherence among older primary care
patients (Kales et al., 2012). In the present study, we
examined treatment attitudes and beliefs as a potential
explanation for race–gender differences in antidepres-
sant adherence. African-American men and women
expressed greater concerns about treatment problems
and less understanding about treatment than White
women, and African-American men expressed signiﬁ-
cantly more negative attitudes toward health providers
than White and African-American women. African-
American women were signiﬁcantly less likely than
White men and women to endorse their antidepres-
sant as their most important medication. Fewer con-
cerns about treatment problems and indicating the
antidepressant as the most important medication
remained signiﬁcantly associated with adherence in
adjusted models. When treatment problems and med-
ication importance were examined in logistic regres-
sion models with race–gender group indicators, each
remained signiﬁcantly associated with adherence, after
controlling for baseline covariates. However, the dis-
parity between White and African-American women
was no longer statistically signiﬁcant, suggesting that
these attitudes may have accounted for the race–
gender differences found in the previous study.
The Treatment Problems subscale was the only
PARC-D subscale that was signiﬁcantly associated
with antidepressant adherence. Subjects who endorsed
concerns related to antidepressants were less likely to
be adherent to antidepressants. This is consistent with
Table 3 Covariate adjusteda odds ratio estimates based on logistic regression models for antidepressant adherence at 4-month follow-up
Variable AORa (95% CI) AORa,b (95% CI) AORa (95% CI) AORa (95% CI)
Racec
AA women (reference) 1.0 1.0 1.0
AA men 1.87 (0.65–5.33) 2.03 (0.68–6.05) 1.64 (0.56–4.84)
White men 2.29 (0.81–6.50) 2.14 (0.74–6.26) 1.92 (0.65–5.70)
White women 3.05 (1.06–8.81)* 2.60 (0.88–7.68) 2.56 (0.84–7.80)
Stigma 0.95 (0.82–1.09)
Attitude
Intrinsic spirituality 0.84 (0.70–1.00)
Treatment problems 1.27 (1.06–1.52)** 1.26 (1.04–1.51)*
Treatment effectiveness 1.08 (0.94–1.25)
Health providers’ interpersonal skills 1.12 (0.99–1.25)
Patient education, information, and understanding 1.14 (0.92–1.41)
Access 1.15 (0.95–1.39)
Recognition of depression 1.24 (0.97–1.59)
AD importance
AD least important (reference) 1.0 1.0
AD most important 4.96 (1.59–15.47)** 4.48 (1.40–14.30)*
Other drugs most important 1.70 (0.68–4.23) 1.87 (0.72–4.80)
AA, African American; AOR, adjusted odds ratio; CI, conﬁdence interval.
aAdjusted for demographic variables of age, marital status, and education, whether seeing a therapist, illness burden variables of prior treatment of
depression, number of prescribed medications, physical component summary score (PCS), mental component summary score (MCS), depression
score on Patient Health Questionnaire (PHQ total), Hospital Anxiety and Depression score (HADS total), and Anxiety Sensitivity Index (ASI total),
and for functional status variables of Katz index of independence in activities of daily living (Katz total), instrumental activities of daily living (IADL
total), and Weschler memory scale, all assessed at baseline.
bAOR estimates for stigma, each of the seven attitude subscales, and the three levels of AD importance were based on ﬁtting separate logistic regression
models to assess their individual effect independent of the baseline demographic variables, illness burden variables, and functional status variables.a
cPost-hoc contrasts also showed that the ORs were 1.23 for White men versus Black men (95% CI 0.44–3.43), 1.63 for White women versus Black
men (95% CI 0.57–4.66), and 1.33 for White women versus White men (95% CI 0.52–3.41).
*p< 0.05.
**p< 0.01.
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past work among African-American patients ﬁnding
that concerns about antidepressants such as side
effects and addiction potential were extremely impor-
tant to patients (Cooper et al., 2000). Providing
patients with accurate information about the risks
and beneﬁts of antidepressant use may allay some of
these concerns and could potentially improve antide-
pressant adherence.
Patients who considered antidepressants to be their
“most important” medication were signiﬁcantly more
likely to be adherent than patients who considered
antidepressants to be the “least important.” African-
American women were signiﬁcantly less likely to rank
their antidepressant medication as most important
compared with the other race–gender groups. Our
ﬁnding that the majority of older adults in primary
care do not consider their antidepressants as their
most important medication is consistent with prior re-
search (Proctor et al., 2008). Patients may view their
antidepressant use as less necessary than taking their
other medications for “medical” conditions resulting
in antidepressant non-adherence, potentially viewing
their antidepressant use as “discretionary.” While pri-
oritizing medications for “medical” conditions may be
rational for patients with severe disease (for example,
extremely low cardiac output), our ﬁndings indicate
that it may also be a predictor of antidepressant non-
adherence, particularly in African-American women.
Some patients may also consider antidepressants a
less important medication because they believe they
have other options for coping with their symptoms
(psychotherapy, religious practices, and social sup-
port). Although antidepressant treatment is often the
evidence-based choice for older adults seen in primary
care settings, psychotherapy may be the preferred
choice (Gum et al., 2006, Raue et al., 2009, van Schaik
et al., 2004). In this study, 19% of African Americans
and 14% of Whites reported that they were seeing a
therapist at baseline; however, among those who were
non-adherent at 4months, only four African Americans
and threeWhites reported seeing a therapist, and we did
not ﬁnd seeing a therapist to be signiﬁcantly associated
with 4-month adherence (results not shown). Future
studies should investigate whether patients who con-
sider their antidepressants less important cope with
their depression symptoms in other ways.
Although we found that older African Americans
endorsed signiﬁcantly greater personal spirituality
than White subjects, after controlling for other vari-
ables, personal spirituality was not associated with ad-
herence. Prior work has found that African Americans
are signiﬁcantly more likely than White subjects to
rate intrinsic spirituality as an important component
of depression care (Cooper et al., 2001). It is unclear
if spirituality serves as a barrier to effective depression
care, such as treatment adherence among African-
American patients (Cooper et al., 2003). Some studies
have suggested an association between religious
participation and improved treatment participation
and depression outcomes in the older adults (Wittink
et al., 2009, Bosworth et al., 2003, Koenig, 1998). The
relationship between spirituality and adherence is
complex and merits further study.
We also did not ﬁnd perceived stigma to be signif-
icantly associated with race–gender differences in ad-
herence. Another facet of stigma is internalized
stigma, which refers to the devaluation, shame, and se-
crecy triggered by applying negative stereotypes associ-
ated with mental illness to oneself (Corrigan and
Penn, 1999). Although we did not examine mediation
in the present study, recent work (Conner et al., 2009,
Brown et al., 2010, Conner et al., 2010) has found in-
ternalized stigma to partially mediate the relationship
between attitudes and treatment in older African-
American subjects.
The main adherence differences found were be-
tween African-American and white women. The rela-
tionship between adherence and race–gender has
received relatively little focus to date. Conventional
wisdom holds that women are more willing to engage
in depression treatment than men, but this may hold
up less well in non-White populations. Previous work
describing greater rates of prior treatment and current
antidepressant use among women as compared with
men may have come from predominately White sam-
ples (Kales et al., 2012). The ﬁnding of the lowest ad-
herence rates among African-American women clearly
merits further study, particularly given the association
with potentially modiﬁable attitudes found here.
This study has several limitations. The sample was
recruited from primary care clinics in southeastern
Michigan; results may not be generalizable to other
geographic areas. Although we used a well-validated
self-report measure (BMQ) to examine adherence,
electronic monitoring or pill counts may have yielded
more precise results (Unützer et al., 1997). Lastly, we
did not measure internalized stigma; a greater rela-
tionship between stigma and adherence may have
been found had we done so.
This study provides important new information
about attitudes and beliefs related to antidepressant
adherence. Attitudes are potentially modiﬁable
through improved patient–provider communication
and culturally sensitive psycho-education and thera-
peutic interventions that could include the following:
(i) discussing concerns related to antidepressants such
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as worries about side effects or addiction; (ii) provid-
ing easy to understand educational materials; or
(iii) utilizing motivational enhancement techniques,
such as conducting decisional balances. Future re-
search should further explore adherence in African-
American women, other treatment attitudes and
beliefs that may be related to poor adherence, the rela-
tionship between the multiple dimensions of stigma
and antidepressant adherence, and innovative ways
in which alternative coping strategies such as religious
practices, social support, and psychotherapy may be
used to improve antidepressant adherence.
Conﬂict of interest
None declared.
Key points
• African Americans expressed greater concerns
about treatment problems including possible
side effects associated with depression treatment
and less understanding about depression
treatment than White female subjects.
• African-American women were less likely to
endorse their antidepressant as being their
most important medication as compared with
White female and White male subjects.
• Concerns about treatment problems and
medication importance were associated with
race–gender differences in adherence.
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